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Key points  
Eradication of HCV following anti-HCV therapy was not associated with significant changes in 































Background: Little is known about the effects of eradication of HCV on bone mineral 
density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfected patients. 
Methods: We prospectively assessed standardized BMD (sBMD) at the lumbar spine 
and femoral neck, World Health Organization (WHO) BMD categories at both sites, and 
plasma concentrations of soluble receptor activator of nuclear factor-kappa ligand 
(sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV 
therapy) and at 96 weeks. 
Results: A total of 238 patients were included, median age 49.5 years, 76.5% males, 
48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 
cells/mm3, 86.6% with HIV-1 RNA < 50 copies/mL. The prevalence of osteoporosis at 
baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, 
respectively. Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-
RBV) plus one direct-acting antiviral in 53.4%, PegIFN-RBV in 34.5%, and 
sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained viral 
response (SVR). No significant effect of SVR was observed on sBMD for the interaction 
between time and SVR either in the LS (P=0.801) or the FN (P=0.911). Likewise, no 
significant effect of SVR was observed in plasma levels of sRANKL (P=0.205), OPG 
(P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction between time and SVR. 
No significant correlation was found between fibrosis by transient elastography, and LS 






























Conclusions: SVR was not associated with significant changes in BMD nor biomarkers of 
bone remodeling in HIV/HCV-coinfected persons.  
Key Words 
































Osteoporosis and bone fractures are common among patients with liver cirrhosis [1, 2], 
particularly among those of advanced age, smokers, postmenopausal women, individuals with 
alcoholism, malnourished individuals, and in liver disease of cholestatic etiology [3].  
Nevertheless, viral hepatitis has been associated with reduced bone mineral density (BMD), and 
several factors have been hypothesized to contribute to it. On the one hand, elevated serum 
levels of inflammatory cytokines could inhibit bone formation and increase bone resorption. On 
the other hand, progressive hepatitis-induced liver dysfunction may be associated with reduced 
hepatic hydroxylation of vitamin D, hypogonadism, and impaired hepatic production of insulin-
like growth factor-1 and osteoprotegerin, both of which promote bone formation. The 
association between non-cirrhotic chronic Hepatitis C virus (HCV) infection and osteoporosis is, 
however, controversial [4]. 
The prevalence of osteoporosis in Human Immunodeficiency Virus (HIV)-infected persons is 
approximately 15%, which is more than three times greater than reported in HIV uninfected 
controls [5]. HCV infection has been associated with an increased risk of osteoporosis and bone 
fractures in HIV-infected persons [6]. However, the mechanism is not well understood and may 
involve the severity of the liver disease, a reduction BMD, microstructural abnormalities 
associated with HCV infection, and increased levels of inflammatory markers [7-10]. 
Nevertheless, unmeasured confounders, including behavioral and nutritional factors, have not 
been completely ruled out.  
Little is known about the effects of sustained viral response (SVR) on BMD in patients with HCV 
infection [11-13], and to the best of our knowledge, the subject has not been assessed in 
patients coinfected with HIV/HCV. Our study's main objective was to assess the effects of 
eradication of HCV on BMD and biomarkers of bone remodeling in HIV/HCV-coinfected 
individuals. Knowing the effects of therapeutic HCV eradication on BMD may contribute to 





























Besides, this research question is clinically relevant in the current era of direct-acting anti-HCV 
agents (DAAs) is which sustained viral response (SVR) can be achieved in most HIV/HCV-
infected individuals, even in those with advanced liver disease [14]. 
Methods 
Design and Patient Selection 
Ours was a multicenter prospective study of HIV/HCV-coinfected patients initiating anti-HCV 
therapy between Feb 2012 and Feb 2016 in 14 centers distributed across 5 regions in Spain: 
Madrid (N=7), Valencia (N=3) Catalonia (N=2), Basque Country (N=1), and Andalusia (N=1). The 
cohort included both naïve and anti-HCV therapy experienced HIV/HCV-coinfected patients 
with compensated liver disease, who initiated treatment against HCV. Infectious-diseases 
physicians decided to administer anti-HCV therapy and regimen selection at each institution 
according to contemporary guidelines. The ethics committees of Hospital General Universitario 
Gregorio Marañón and Hospital Universitario La Paz approved the study. This work was 
conducted following the Declaration of Helsinki. All patients provided written, informed consent 
for the study. All the centers were monitored (following the last patient's first visit, interim 
monitoring, and following the last patient's last visit) to verify that all the information in the 
case report form was consistent with the patient's clinical history.  
Investigation 
Baseline was the date of anti-HCV treatment initiation. Patients with an undetectable serum 
HCV-RNA level 12 weeks after discontinuation of anti-HCV therapy were classified as having 
SVR. Clinical and laboratory variables were collected at baseline, every four weeks during anti-
HCV treatment, and every 12 weeks after discontinuation of therapy, until 96 weeks after the 
initiation of treatment. All the information was recorded at each institution using a shared 





























Baseline variables included demographics, height and weight, and systolic and diastolic blood 
pressure. It also included clinical information related to HIV, HCV-related liver disease, other 
comorbid conditions, prior anti-HCV therapy, whether or not patients were receiving cART or 
other medications (including opioid substitution therapy), smoking history, ongoing alcohol 
intake more than 50 g/day. Laboratory tests included complete blood counts, coagulation tests, 
a comprehensive serum biochemistry profile (including serum lipids, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), albumin, creatinine, 25 OH vitamin D, thyroxine [T4], 
thyrotropin [TSH], and parathyroid hormone [PTH]), HIV-1-RNA, and HCV-RNA quantification, 
HCV genotype, hepatitis B surface antigen (HBsAg), and determination of CD4 + and CD8 + T 
lymphocytes.  
Assessment of liver fibrosis 
Liver fibrosis at baseline was assessed using transient elastography (FibroScan; Echosens, Paris, 
France) performed by trained operators. Results were expressed in kilopascals (kPa) with a 
range of 2.5–75 kPa. We considered 10 acquisitions with a success rate of at least 60% and an 
interquartile range less than 30% of the median value as representative measurements of liver 
stiffness. Fasting was not routinely required before the examination. Cirrhosis was defined as a 
liver stiffness value  12.5 kPa [15] or by liver biopsy.  
Assessment of bone mineral density 
BMD was assessed using dual-energy X-ray absorptiometry (DXA) at the lumbar spine and 
femoral neck. In accordance with the World Health Organization (WHO) definitions, 
osteoporosis was defined as a T score of −2.5 standard deviation (SD) or lower and osteopenia 
as a T score between −1 and −2.5 SD [16]. Normal status was defined as a T score above −1 SD. 
As different densitometers were used (Hologic® [n=8], Lunar® [n=3], and Norland® [n=2]), 






























Biomarkers of bone remodeling  
Plasma samples were taken at baseline and 96 weeks after the initiation of therapy and stored 
frozen in the HIV BioBank of Hospital General Universitario Gregorio Marañón 
(http://hivhgmbiobank.com). Two biomarkers of bone formation and resorption were 
determined in these samples: soluble receptor activator of nuclear factor-appa ligand 
(sRANKL) and osteoprotegerin (OPG) [19]. These biomarkers are implicated in the 
pathogenesis of low bone density in HIV-infected patients [20, 21], and different studies have 
found an association between imbalances of these biomarkers and BMD loss in ART-treated 
HIV-infected individuals [22, 23]. Both biomarkers were measured by ProcartaPlexTM 
multiplex immunoassay (Bender MedSystems GmbH, Vienna, Austria) using a Luminex 200™ 
analyzer (Luminex Corporation, Austin, TX, United States) and according to the manufacturer’s 
specifications [24]. After all clinical tests were completed, the sRANKL/OPG ratio was 
calculated. 
Statistics 
For the descriptive study, values were expressed as absolute number and percentage, and 
median and interquartile range (IQR). Differences between groups were analyzed using the chi-
square test, t-test, or Mann-Whitney test, as appropriate. Normality was analyzed using the 
Kolmogorov–Smirnov test. Pearson correlation and Spearman’s rho were used to assessing the 
correlations between sBMD and liver stiffness. Univariable and multivariable logistic regression 
analyses were used to identify variables associated with osteoporosis at the lumbar spine and 
the femoral neck at baseline. Variables analyzed included age, sex, body mass index (BMI), 
current smoking, alcohol intake > 50 g/day, methadone use, history of injection drug use (IDU), 
Centers for Disease Control and Prevention (CDC) clinical category, tenofovir disoproxil 
fumarate (TDF) use, HIV-RNA, CD4+ cell count, nadir CD4+ cell count, CD4+/CD8+ ratio, HIV-
RNA, HCV genotype, HCV-RNA, liver stiffness, 25 OH vitamin D, T4, TSH, and PTH. Variables 





























univariable analysis. Linear mixed models for longitudinal data were used in analyses to 
account for repeated measures of sBMD, with SVR and time and their interaction taken as fixed 
effects, and the patient as a random effect. Least-square means and their 95% confidence 
intervals (CI) are reported for these models. Besides, to study changes between baseline and 
week 96 WHO BMD categories, tests for repeated measures were used (paired t-test and 
Wilcoxon test). IBM SPSS Statistics for Windows, Version 21.0, was used for all calculations. All 
statistical tests were performed two-sided, and a P-value of <0.05 was considered statistically 
significant. 
Results 
Overall, 238 patients were included in the study, 145 of which (60.9%) achieved SVR; the full 
characteristics of these patients, categorized by whether or not achieved SVR, are shown in 
Table 1. In brief, 76.5% were male, the median age was 49.5 years, 27.3% had had prior AIDS-
defining conditions, 98.3% were on cART, the median baseline CD4 cell count was 527 
cells/mm3, 86.6% had an undetectable HIV viral load, 62.6% were infected with HCV genotype 
1, the median HCV-RNA load was 6.4 log10 IU/mL, and 3.4% were HBsAg positive. Liver 
cirrhosis was detected in 48.3% of patients, and 11.3% had received prior anti-HCV therapy. 
Alcohol intake > 50 g/d was reported by 2.1% patients, 68.1% were current smokers, 13.0% 
had arterial hypertension, and 8.4% had diabetes mellitus. Anti-HCV regimens included 
pegylated interferon (Peg-IFN) plus ribavirin (RBV) 34.5%, Peg-IFN plus RBV plus a first-
generation anti-HCV protease inhibitor (PI) 47.5%, Peg-IFN plus RBV plus daclatasvir 5.9%, and 
sofosbuvir plus RBV 12.2%. HCV-RNA and the type of anti-HCV therapy were the only baseline 
variables in which significant differences were found between responders and non-responders.  
The overall prevalence of osteoporosis at the lumbar spine and femoral neck in HIV/HCV-
coinfected patients was 17.6% and 7.2%, respectively, without significant differences between 
responders and non-responders (Table 1). Logistic regression analyses of variables associated 





























Lower BMI was the only variable independently associated with osteoporosis at the lumbar 
spine (adjusted odds ratio ([aOR] 0.853; 95% confidence interval [CI] 0.735 – 0.991, P=0.037). 
BMI was also associated with osteoporosis at the femoral neck in the univariable analysis but 
not in multivariable analysis.  
No significant correlation was found between liver fibrosis, assessed by transient elastography, 
and lumbar spine and femoral neck sBMD, at baseline, and week 96 Figure 1.  
Changes in sBMD in the lumbar spine and femoral neck from baseline to 96 weeks in responders 
and non-responders are shown in Figure 2. No significant effect of SVR was observed on sBMD 
for the interaction between time and SVR in the lumbar spine (P=0.801) or the femoral neck 
(P=0.911). The median (95% CI) change from baseline to week 96 in sBMD at the lumbar spine 
was -0.007 (-0.033 – 0.032) g/cm2 in responders and -0.006 (-0.028 – 0.027) g/cm2 in non-
responders. Likewise, the change in sBMD at the femoral neck was -0.023 (-0.065 – 0.012) 
g/cm2 in responders and -0.024 (-0.052 – 0.019) g/cm2 in non-responders. Two sensitivity 
analyses were carried out, the first without the eight patients that were coinfected with HBV, 
and the second without the four patients not on ART; the results of these sensitivity analyses 
did not change the results found in the primary analysis (data not shown).  
No significant changes in BMD WHO categories from baseline to 96 weeks were found in the 
lumbar spine and femoral neck either in responders or non-responders (Figure 4).  
Changes in plasma levels of sRANKL, OPG, and sRANKL/OPG ratio from baseline to 96 weeks in 
responders are shown in Figure 4. No significant effect of SVR was observed in plasma levels of 
sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction 
between time and SVR. 
Discussion 
In this prospective study, with 238 HIV/HCV-coinfected patients half of which had liver 





























did not observe an association between HCV eradication and significant changes in sBMD, BMD 
WHO categories, and plasma levels of biomarkers of bone remodeling. To the best of our 
knowledge, ours is the largest prospective study analyzing the effects of HCV eradication after 
anti-HCV therapy in patients with chronic HCV infection, and the first analyzing this issue 
among HIV/HCV-coinfected patients.  
We found that among the study population, the prevalence of osteoporosis at the lumbar spine 
and femoral neck was 17.6% and 7.2% respectively, differences that can be explained because 
lumbar spine consists of trabecular bone, which is more metabolically active with a higher rate 
of turnover and may be affected earlier and more severely in comparison with the cortical bone 
of the femoral neck [25]. Lower BMI was the only baseline variable associated with 
osteoporosis. It must be considered, however, that we could not assess appropriately advanced 
age and female sex, as patients in our cohort were within a narrow age range in their forties and 
fifties, and more than three quarters were males. We did not find a correlation between liver 
fibrosis, assessed by transient elastography and sBMD at baseline and week 96 after initiation of 
anti-HCV therapy, something consistent with what has been found in previously published 
studies with a limited number of patients [11-13]. 
The effects of SVR on BMD have been previously assessed in small studies, including HCV-
monoinfected patients. In a prospective study with 36 treatment naïve non-cirrhotic patients 
with chronic hepatitis C with SVR following Peg-IFN plus RBV, BMD values at the lumbar spine 
and the femoral neck at 24 and 48 weeks of antiviral therapy and 48 weeks after the end of 
treatment were significantly higher in comparison with baseline values [11]. A limitation of this 
study is the non-availability of comparable data on the patients who did not achieve SVR. In a 
prospective study with 46 non-cirrhotic children with chronic hepatitis C treated with Peg-IFN 
plus RBV, 23 of which achieved SVR, follow-up DXA scans results 24 weeks after the end of 
treatment showed statistically significant improvement in BMD from baseline; however, an 
effect of SVR on BMD could not be evaluated [12]. In a study with 30 non-cirrhotic patients with 





























significantly by the end of 48-week therapy in comparison with baseline but decreased by the 
end 24-week follow-up period without significant differences between patients with SVR and 
patients with viral relapse [13]. The authors also found a decrease in osteocalcin and C-terminal 
propeptide of type I collagen during Peg-IFN plus RBV therapy supporting the findings of the 
DXA measurements. 
Our study is limited because we used different densitometers to assess BMD, something that we 
tried to correct calculating sBMD according to published equations. Another limitation is the 
lack of central reading of DXA scans. It also needs to be mentioned that almost 90% of our 
patients received Peg-IFN and 100% RBV, both of which modulate bone metabolism, with IFN 
inhibiting excessive osteoclastogenesis resulting in reduced bone resorption [26, 27], and RBV, 
exhibiting oppositional effects [28, 29]. Other limitations include the lack of an HCV-
monoinfected group and the lack of an age, sex-, and race matched control group. However, the 
study has the strengths of the prospective design, the large sample size, the assessment of both 
sBMD and biomarkers of bone remodeling at baseline and 96 weeks after treatment initiation, 
and the fact that responders and non-responders were well matched in many relevant 
characteristics limiting the possibility of confounding.  
In conclusion, in this prospective cohort of HIV/HCV-coinfected patients, half of which had 
compensated cirrhosis, no significant correlation was found between liver-stiffness and BMD at 
baseline and week 96 after initiation of anti-HCV therapy. Besides, in the medium term, 
eradication of HCV following anti-HCV therapy was not associated with significant changes in 
sBMD, BMD WHO categories, and plasma levels of biomarkers of bone remodeling. Our findings 
do not support a causal association between HCV infection and reduced BMD in HIV/HCV-
coinfected persons with compensated liver disease. They suggest that lifestyle and other factors 
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Figure 1.  
Pearson and Spearman correlations between lumbar spine and femoral neck bone mineral 
density and liver fibrosis assessed by transient elastography at baseline (A) and at 96 weeks 
(B). Abbreviations: sBMD, standardized bone mineral density 
Figure 2.  
Estimated means (95% confidence interval) of bone mineral density in the lumbar spine 
and femoral neck at baseline and 96 weeks in responders and non-responders to anti-
HCV therapy. Abbreviations: sBMD, standardized bone mineral density; SVR, sustained 
viral response. 
Figure 3.  
Changes in bone mineral density, World Health Organization (WHO) categories from baseline to 
96 weeks at the lumbar spine for responders (A) and non-responders (B); and at the femoral 
neck in responders (C) and non-responders (D). Abbreviations: sBMD, standardized bone 
mineral density; SVR, sustained viral response. 
Figure 4. Estimated means (95% confidence interval) of plasma biomarkers concentrations at 
baseline and 96 weeks in responders and non-responders to anti-HCV therapy: sRANKL (A), OPG (B), 
and sRANKL/OPG ratio (C).  Abbreviations: SVR, sustained viral response; sRANKL, soluble receptor 


































Table 1. Baseline characteristics of the study population 
Characteristic  No SVR (n=93) SVR (n=145) P TOTAL (n=238) 
Male sex, No. (%)  66 (70.9) 116 (80.0) 0.109 182 (76.5) 
Age, years, median (IQR) (baseline) 49.1 (46.6 - 52.6) 49.7 (46.3 - 53.2) 0.629 49.5 (46.4 - 53) 
BMI, median (IQR) 24.1 (22.1 - 26.1) 24.4 (21.5 - 27.3) 0.460 24.2 (21.8 - 26.6) 
Prior injection drug use, No. (%)  73 (78.5) 107 (73.8) 0.410 180 (75.6) 
Methadone therapy, No. (%) 13 (14.0) 16 (11.0) 0.707 29 (12.2) 
CDC disease category C, No. (%) 31 (33.3) 34 (23.4) 0.229 65 (27.3) 
CD4+, nadir, cells/mm3, median (IQR) 160 (69 - 253) 162 (84 - 246) 0.901 160 (72 - 250) 
cART during anti-HCV treatment, No. (%)a 92 (98.9) 142 (97.9) 0.708 234 (98.3) 
Antiretroviral drugs, No. (%)     0.561   
Tenofovir disoproxil fumarate 56 (60.9) 86 (60.6) 142 (60.7) 
Emtricitabine 53 (57.6) 83 (58.5) 136 (58.1) 





























Abacavir 13 (14.1) 32 (22.5) 45 (19.2) 
Raltegravir 35 (38.0) 54 (38.0) 89 (38.0) 
Darunavir/ritonavir 21 (22.8) 22 (15.5) 43 (18.4) 
Atazanavir/ritonavir 14 (15.2) 24 (16.9) 38 (16.2) 
Lopinavir/ritonavir 4 (4.3) 5 (3.5) 9 (3.8) 
Fosamprenavir/ritonavir 3 (3.3) 1 (0.7) 4 (1.7) 
Etravirine 18 (19.6) 23 (16.2) 41 (17.5) 
Efavirenz 15 (16.3) 19 (13.4) 34 (14.5) 
Rilpivirine 3 (3.3) 6 (4.2) 9 (3.8) 
Nevirapine 2 (2.2) 5 (3.5) 7 (3.0) 
Maraviroc 0 (0) 2 (1.4) 2 (0.9) 
CD4+, baseline, cells/mm3, median (IQR)  550 (372 - 822) 518 (385 - 772) 0.556 527 (380 - 803) 
Undetectable HIV RNA load at baseline, No. (%) 77 (82.8) 129 (89) 0.230 206 (86.6) 
Prior anti-HCV therapy, No. (%) 9 (9.7) 18 (12.4) 0.516 27 (11.3) 







1 55 (59.1) 94 (64.9) 149 (62.6) 
2 3 (3.2) 2 (1.4) 5 (2.1) 
3 19 (20.4) 24 (16.6) 43 (18.1) 
4 10 (10.8) 10 (6.9) 20 (8.4) 





























Unknown 0 (0) 1 (0.7) 1 (0.4) 
HCV-RNA, Log10 IU/mL, median (IQR) 6.5 (6.1 - 6.9) 6.3 (5.8 - 6.6) 0.001 6.4 (5.9 - 6.7) 
HBsAg positivity, No. (%) 3 (3.2) 5 (3.4) 0.655 8 (3.4) 
Serum albumin, g/dL, median (IQR) 4.2 (3.95 - 4.5) 4.3 (4.1 - 4.6) 0.030 4.3 (4.0 - 4.6) 
Liver cirrhosis, No. (%) (METAVIR 4 or TE>12,5) 41 (44.1) 74 (51) 0.295 115 (48.3) 
Current alcohol intake > 50 g/d, No. (%)  1 (1.1) 4 (2.8) 0.560 5 (2.1) 
Diabetes mellitus, No. (%)b 9 (9.7) 11 (7.6) 0.570 20 (8.4) 
Current smoking, No. (%) 65 (69.9) 97 (66.9) 0.910 162 (68.1) 
Arterial hypertension, No. (%)b 14 (15.1) 17 (11.7) 0.456 31 (13) 
Anti-HCV therapy, No. (%)     0.003   
Peg-IFN + RBV 29 (31.2) 53 (36.6) 82 (34.5) 
Peg-IFN + RBV + HCV protease inhibitor 36 (38.7) 77 (53.1) 113 (47.5) 
Peg-IFN + RBV + Daclatasvir 6 (6.5) 8 (5.5) 14 (5.9) 
Sofosbuvir + RBV 22 (23.7) 7 (4.8) 29 (12.2) 
WHO diagnostic classification at the lumbar spine*– No./with data (%)   0.825  
Osteoporosis  13/82 (15.9) 24/128 (18.8) 37/210 (17.6) 
Osteopenia 32/82 (39.0) 42/128 (32.8) 74/210 (35.2) 
Normal 37/82 (45.1) 62/128 (48.4) 99/210 (47.1) 
WHO diagnostic classification at femoral neck#– No./with data (%)   0.260  





























Osteopenia 44/81 (54.3) 54/127 (42.5) 98/208 (47.1) 
Normal 30/81 (37.0) 65/127 (51.2) 95/208 (45.7) 
 
aThree patients were not receiving ART because they were elite controllers of HIV (i.e., HIV-infected patients with spontaneous control 
of HIV replication at undetectable levels). One patient was not receiving ART because he was a long-term non-progressors with a CD4+ 
cell count of 633 cells/mm3 and an HIV-RNA load of 299 copies/mL. 
bDiabetes and hypertension were defined as diagnoses included in the medical record 
cBaseline BMD at the lumbar spine was determined in 210 patients. 
dBaseline BMD at the femoral neck was determined in 208 patients 
 
Abbreviations: SVR, sustained viral response; IQR, interquartile range, BMI, body mass index; CDC, Centers for Disease Control and 
Prevention; cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; HCV, hepatitis C virus; RNA, ribonucleic 




































Table 2. Logistic regression analysis of variables associated with osteoporosis at the lumbar spine and the femoral neck at baseline     
 Lumbar Spine Femoral Neck 
 Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
Variable OR 95%CI P aOR 95%CI P OR 95%CI P aOR 95%CI P 
Age 1.029 0.95 - 1.114 0.485 1.037 0.933 - 1.152 0.505 1.063 0.99 - 1.142 0.091 1.100 0.984 - 1.231 0.095 
Male sex 1.199 0.509 - 2.826 0.678 1.400 0.559 - 3.503 0.472 0.608 0.197 - 1.877 0.387 0.404 0.089 - 1.825 0.239 
BMI 0.853 0.751 - 0.969 0.015 0.853 0.735 - 0.991 0.037 0.833 0.712 - 0.975 0.023 0.830 0.678 - 1.017 0.072 
History of IDU 0.893 0.399 - 1.998 0.783    0.910 0.276 - 3.001 0.877    
CD4+/CD8+ 1.116 0.913 - 1.365 0.285    0.159 0.022 - 1.164 0.070 0.100 0.010 - 1.038 0.054 
Methadone 2.707 1.059 - 6.922 0.038 2.246 0.858 - 5.877 0.099 NA NA NA    
TDF use 0.684 0.334 - 1.397 0.297    0.568 0.197 - 1.636 0.295 1.444 0.392 - 5.328 0.581 
Current smoking 2.181 0.901 - 5.282 0.084 1.796 0.647 - 4.980 0.261 1.815 0.492 - 6.696 0.371    
Alcohol intake > 50 g/day 0.556 0.257 - 1.203 0.136    1.028 0.342 - 3.085 0.961    
Clinical category C (CDC) 0.926 0.415 - 2.069 0.852    1.255 0.408 - 3.855 0.692    
Nadir CD4+ cell count 0.999 0.996 - 1.002 0.471    0.998 0.994 - 1.002 0.275    
CD4+ cell count 0.999 0.998 – 1.000 0.197    0.999 0.996 - 1.001 0.360    
HIV-RNA BLQ 1.254 0.47 - 3.343 0.651    0.982 0.209 - 4.622 0.982    
HCV genotype 3 0.853 0.328 - 2.221 0.744    1.701 0.509 - 5.678 0.388    
Log10 HCV-RNA 1.572 0.895 - 2.761 0.115    0.740 0.386 - 1.417 0.363    





























Vitamin D 0.976 0.946 - 1.007 0.133    0.985 0.949 - 1.023 0.436    
T4 1.025 0.887 - 1.183 0.739    0.926 0.738 - 1.162 0.508    
TSH 0.961 0.863 - 1.07 0.467    0.753 0.462 - 1.228 0.256    
PTH 1.006 0.996 - 1.015 0.249    1.005 0.996 - 1.015 0.273    
 
Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; BMI, body mass index; IDU, injection drug use; TDF, tenofovir disoproxil fumarate; 
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